Antnio Lpez-Beltrn

List of Publications by Citations

550 papers	16,272 citations	64 h-index	105 g-index
665 ext. papers	19,017 ext. citations	5.3 avg, IF	6.56 L-index

#	Paper	IF	Citations
550	The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. *American Journal of Surgical Pathology*, **2005**, 29, 1228-42	6.7	1909
549	2004 WHO classification of the renal tumors of the adults. *European Urology*, **2006**, 49, 798-805	10.2	608
548	Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. *European Urology*, **2015**, 67, 85-97	10.2	292
547	Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. *Cancer*, **2004** , 101, 957-62	6.4	230
546	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. *Modern Pathology*, **2018**, 31, 24-38	9.8	206
545	The 2004 WHO classification of bladder tumors: a summary and commentary. *International Journal of Surgical Pathology*, **2005**, 13, 143-53	1.2	176
544	Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. *Human Pathology*, **2006**, 37, 1371-88	3.7	172
543	Molecular pathology of lung cancer: key to personalized medicine. *Modern Pathology*, **2012**, 25, 347-69	9.8	171
542	2009 update on the classification of renal epithelial tumors in adults. *International Journal of Urology*, **2009**, 16, 432-43	2.3	170
541	Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. *American Journal of Pathology*, **2005**, 166, 1533-9	5.8	151
540	Bladder cancer: translating molecular genetic insights into clinical practice. *Human Pathology*, **2011**, 42, 455-81	3.7	149
539	Molecular biology of prostatic intraepithelial neoplasia. *Prostate*, **1996**, 29, 117-34	4.2	148
538	Tuberous sclerosis-associated renal cell carcinoma: a clinicopathologic study of 57 separate carcinomas in 18 patients. *American Journal of Surgical Pathology*, **2014**, 38, 1457-67	6.7	139
537	Molecular evidence supporting field effect in urothelial carcinogenesis. *Clinical Cancer Research*, **2005**, 11, 6512-9	12.9	134
536	Renal tumors: diagnostic and prognostic biomarkers. *American Journal of Surgical Pathology*, **2013**, 37, 1518-31	6.7	126
535	Staging and reporting of urothelial carcinoma of the urinary bladder. *Modern Pathology*, **2009**, 22 Suppl 2, S70-95	9.8	126
534	Multilocular Cystic Renal Cell Carcinoma. *American Journal of Clinical Pathology*, **2006**, 125, 217-222	1.9	124

533	Non-invasive urothelial neoplasms: according to the most recent WHO classification. *European Urology*, **2004**, 46, 170-6	10.2	123
532	Thyroid transcription factor 1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. *Human Pathology*, **2005**, 36, 718-23	3.7	120
531	Evidence for common clonal origin of multifocal lung cancers. *Journal of the National Cancer Institute*, **2009**, 101, 560-70	9.7	118
530	Metabolic phenotype of bladder cancer. *Cancer Treatment Reviews*, **2016**, 45, 46-57	14.4	117
529	Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. *American Journal of Surgical Pathology*, **2014**, 38, e20-34	6.7	114
528	Standardization of Gleason grading among 337 European pathologists. *Histopathology*, **2013**, 62, 247-56	7.3	107
527	ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. *Modern Pathology*, **2011**, 24, 1120-7	9.8	104
526	A working group classification of focal prostate atrophy lesions. *American Journal of Surgical Pathology*, **2006**, 30, 1281-91	6.7	97
525	Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. *American Journal of Surgical Pathology*, **2013**, 37, 1505-17	6.7	96
524	Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. *Human Pathology*, **2009**, 40, 10-29	3.7	94
523	Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder. *Human Pathology*, **2014**, 45, 1473-82	3.7	92
522	Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. *American Journal of Surgical Pathology*, **2010**, 34, 1367-76	6.7	91
521	Gleason grading of prostate cancer in needle biopsies or radical prostatectomy specimens: contemporary approach, current clinical significance and sources of pathology discrepancies. *BJU International*, **2005**, 95, 1146-52	5.6	91
520	Lymphoepithelioma-like carcinoma of the urinary bladder: a clinicopathologic study of 13 cases. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2001**, 438, 552-7	5.1	91
519	Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful?. *Archives of Pathology and Laboratory Medicine*, **2012**, 136, 410-7	5	88
518	Plasmacytoid urothelial carcinoma of the bladder. *Human Pathology*, **2009**, 40, 1023-8	3.7	88
517	Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. *American Journal of Surgical Pathology*, **2011**, 35, e34-46	6.7	87
516	Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. *European Urology*, **2004**, 45, 257-66	10.2	87

515	Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2002**, 440, 3-11	5.1	87
514	Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow-up. *Urology*, **1997**, 50, 427-31	1.6	86
513	Staging of prostate cancer. *Histopathology*, **2012**, 60, 87-117	7.3	84
512	Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. *Clinical Cancer Research*, **2005**, 11, 7226-33	12.9	84
511	Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. *Modern Pathology*, **2010**, 23, 931-6	9.8	82
510	Soft tissue tumors of the urinary bladder, Part I: myofibroblastic proliferations, benign neoplasms, and tumors of uncertain malignant potential. *Human Pathology*, **2007**, 38, 807-23	3.7	80
509	Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. *Modern Pathology*, **2015**, 28, 612-30	9.8	79
508	Inflammatory myofibroblastic tumors of the kidney: a clinicopathologic and immunohistochemical study of 12 cases. *American Journal of Surgical Pathology*, **2003**, 27, 658-66	6.7	78
507	Assessment of prostate carcinoma in core needle biopsy--definition of minimal criteria for the diagnosis of cancer in biopsy material. *Cancer*, **1996**, 78, 376-81	6.4	76
506	Biomarkers in bladder cancer: translational and clinical implications. *Critical Reviews in Oncology/Hematology*, **2014**, 89, 73-111	7	75
505	The plasmacytoid carcinoma of the bladder--rare variant of aggressive urothelial carcinoma. *International Journal of Cancer*, **2011**, 129, 346-54	7.5	75
504	Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. *BJU International*, **2009**, 103, 1464-70	5.6	75
503	Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors. *European Urology*, **2010**, 58, 655-68	10.2	73
502	Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. *Modern Pathology*, **2006**, 19, 1395-401	9.8	73
501	Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. *American Journal of Surgical Pathology*, **2007**, 31, 1861-7	6.7	72
500	Lymphoepithelioma-like carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, and molecular features. *American Journal of Surgical Pathology*, **2011**, 35, 474-83	6.7	69
499	Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. *Human Pathology*, **2010**, 41, 155-62	3.7	69
498	Soft tissue tumors of the urinary bladder Part II: malignant neoplasms. *Human Pathology*, **2007**, 38, 963-977	3.7	69

497	Distinguishing primary adenocarcinoma of the urinary bladder from secondary involvement by colorectal adenocarcinoma: extended immunohistochemical profiles emphasizing novel markers. *Modern Pathology*, **2013**, 26, 725-32	9.8	68
496	Natural history of urothelial inverted papilloma. *Cancer*, **2006**, 107, 2622-7	6.4	68
495	Prognostic Factors in Survival of Patients With Stage Ta and T1 Bladder Urothelial Tumors. *American Journal of Clinical Pathology*, **2004**, 122, 444-452	1.9	68
494	Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. *Clinical Cancer Research*, **2008**, 14, 1947-55	12.9	67
493	Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. *Clinical Cancer Research*, **2007**, 13, 953-7	12.9	66
492	Current pathology keys of renal cell carcinoma. *European Urology*, **2011**, 60, 634-43	10.2	65
491	Inflammatory myofibroblastic tumors of the genitourinary tract--single entity or continuum?. *Journal of Urology*, **2008**, 180, 1235-40	2.5	65
490	Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. *Nature Reviews Urology*, **2007**, 4, 321-32		65
489	Invasive micropapillary urothelial carcinoma of the bladder. *Human Pathology*, **2010**, 41, 1159-64	3.7	64
488	Bladder cancer: clinical and pathological profile. *Scandinavian Journal of Urology and Nephrology*, **2008**, 95-109		64
487	Variants and new entities of bladder cancer. *Histopathology*, **2019**, 74, 77-96	7.3	64
486	BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. *Expert Review of Molecular Diagnostics*, **2015**, 15, 1201-10	3.8	63
485	p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. *Modern Pathology*, **2012**, 25, 1526-33	9.8	63
484	c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. *Modern Pathology*, **2005**, 18, 320-3	9.8	63
483	TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. *Modern Pathology*, **2009**, 22, 113-8	9.8	62
482	Multilocular cystic renal cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma. *American Journal of Surgical Pathology*, **2012**, 36, 1425-33	6.7	62
481	Staging of bladder cancer. *Histopathology*, **2019**, 74, 112-134	7.3	62
480	Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. *Human Pathology*, **2013**, 44, 164-72	3.7	61

479	Malignant perivascular epithelioid cell neoplasm (PEComa) of the urinary bladder with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features. *American Journal of Surgical Pathology*, **2013**, 37, 1619-26	6.7	61
478	The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens. *Human Pathology*, **2007**, 38, 1207-11	3.7	61
477	KIT gene mutation and amplification in dysgerminoma of the ovary. *Cancer*, **2011**, 117, 2096-103	6.4	60
476	The origins of urothelial carcinoma. *Expert Review of Anticancer Therapy*, **2010**, 10, 865-80	3.5	60
475	Immune checkpoint inhibitors for metastatic bladder cancer. *Cancer Treatment Reviews*, **2018**, 64, 11-20	14.4	57
474	Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy. *Molecular Diagnosis and Therapy*, **2016**, 20, 111-7	4.5	57
473	Histologic grading of urothelial carcinoma: a reappraisal. *Human Pathology*, **2012**, 43, 2097-108	3.7	57
472	Laser-assisted microdissection in translational research: theory, technical considerations, and future applications. *Applied Immunohistochemistry and Molecular Morphology*, **2013**, 21, 31-47	1.9	56
471	Primary mediastinal seminoma: a comprehensive assessment integrated with histology, immunohistochemistry, and fluorescence in situ hybridization for chromosome 12p abnormalities in 23 cases. *American Journal of Surgical Pathology*, **2008**, 32, 146-55	6.7	56
470	Multilocular cystic renal cell carcinoma : a report of 45 cases of a kidney tumor of low malignant potential. *American Journal of Clinical Pathology*, **2006**, 125, 217-22	1.9	56
469	Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as "atypical small acinar proliferation suspicious for but not diagnostic of malignancy"). *European Urology*, **2006**, 50, 666-74	10.2	55
468	Secondary neoplasms of the urinary system and male genital organs. *BJU International*, **2009**, 104, 770-6	5.6	54
467	Inverted papilloma of the urinary bladder: a molecular genetic appraisal. *Modern Pathology*, **2006**, 19, 1289-94	9.8	54
466	Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. *Pathology*, **2003**, 35, 484-91	1.6	52
465	Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2011** , 459, 175-82	5.1	51
464	Squamous differentiation in primary urothelial carcinoma of the urinary tract as seen by MAC387 immunohistochemistry. *Journal of Clinical Pathology*, **2007**, 60, 332-5	3.9	51
463	Prostatic adenocarcinoma with atrophic features: malignancy mimicking a benign process. *American Journal of Surgical Pathology*, **1997**, 21, 931-5	6.7	51
462	Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer. *Cancers*, **2021**, 13,	6.6	51

461	Is incidentally detected prostate cancer in patients undergoing radical cystoprostatectomy clinically significant?. *American Journal of Clinical Pathology*, **2009**, 131, 279-83	1.9	50
460	Cystic nephroma and mixed epithelial and stromal tumour of the kidney: opposite ends of the spectrum of the same entity?. *European Urology*, **2008**, 54, 1237-46	10.2	49
459	Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. *Human Pathology*, **2008**, 39, 954-9	3.7	49
458	Telomere shortening and chromosomal abnormalities in intestinal metaplasia of the urinary bladder. *Clinical Cancer Research*, **2007**, 13, 6232-6	12.9	48
457	Clinical utility of immunohistochemistry in the diagnoses of urinary bladder neoplasia. *Applied Immunohistochemistry and Molecular Morphology*, **2010**, 18, 401-10	1.9	48
456	Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification. *Endocrine Pathology*, **2016**, 27, 123-35	4.2	47
455	Glandular lesions of the urinary bladder:clinical significance and differential diagnosis. *Histopathology*, **2011**, 58, 811-34	7.3	47
454	Updates in the Pathologic Diagnosis and Classification of Epithelial Neoplasms of Urachal Origin. *Advances in Anatomic Pathology*, **2016**, 23, 71-83	5.1	46
453	Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the International Society of Urological Pathology consensus conference. *American Journal of Surgical Pathology*, **2014**, 38, 1017-22	6.7	45
452	Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis. *American Journal of Surgical Pathology*, **2010**, 34, 371-6	6.7	45
451	Urethral caruncle: clinicopathologic features of 41 cases. *Human Pathology*, **2012**, 43, 1400-4	3.7	44
450	Epigenetic modulations and lineage plasticity in advanced prostate cancer. *Annals of Oncology*, **2020**, 31, 470-479	10.3	43
449	The reasons behind variation in Gleason grading of prostatic biopsies: areas of agreement and misconception among 266 European pathologists. *Histopathology*, **2014**, 64, 405-11	7.3	43
448	Morphological classification and definition of benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder. *Histopathology*, **2008**, 53, 621-33	7.3	43
447	Germ cell origin of testicular carcinoid tumors. *Clinical Cancer Research*, **2008**, 14, 1393-6	12.9	42
446	Current practice of Gleason grading of prostate carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2006**, 448, 111-8	5.1	42
445	Loss of expression of the SWI/SNF complex is a frequent event in undifferentiated/dedifferentiated urothelial carcinoma of the urinary tract. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2016**, 469, 321-30	5.1	41
444	Prostatic intraepithelial neoplasia: its morphological and molecular diagnosis and clinical significance. *BJU International*, **2011**, 108, 1394-401	5.6	40

443	FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations. *Modern Pathology*, **2009**, 22, 627-32	9.8	40
442	Small cell carcinoma of the urinary bladder--histogenesis, genetics, diagnosis, biomarkers, treatment, and prognosis. *Applied Immunohistochemistry and Molecular Morphology*, **2007**, 15, 8-18	1.9	40
441	Clonal origin of lymph node metastases in bladder carcinoma. *Cancer*, **2005**, 104, 1901-10	6.4	40
440	Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change. *Histopathology*, **2016**, 69, 107-13	7.3	40
439	Role of STAT3 pathway in genitourinary tumors. *Future Science OA*, **2015**, 1, FSO15	2.7	39
438	KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients. *American Journal of Pathology*, **2011**, 179, 540-6	5.8	39
437	Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations. *Histopathology*, **2009**, 55, 161-73	7.3	39
436	Pathological variants of invasive bladder cancer according to their suggested clinical significance. *BJU International*, **2008**, 101, 275-81	5.6	39
435	Rare and unusual histological variants of prostatic carcinoma: clinical significance. *BJU International* , **2008**, 102, 1369-74	5.6	39
434	Evidence for polyclonal origin of multifocal clear cell renal cell carcinoma. *Clinical Cancer Research*, **2008**, 14, 8087-93	12.9	39
433	New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. *Frontiers in Oncology*, **2018**, 8, 653	5.3	39
432	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. *Cancers* , **2020**, 12,	6.6	38
431	Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. *Journal of Molecular Diagnostics*, **2011**, 13, 29-40	5.1	38
430	Molecular determinants of tumor recurrence in the urinary bladder. *Future Oncology*, **2009**, 5, 843-57	3.6	38
429	Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. *Critical Reviews in Oncology/Hematology*, **2010**, 76, 112-26	7	38
428	Neonatal exposure of male rats to estradiol benzoate causes rete testis dilation and backflow impairment of spermatogenesis. *The Anatomical Record*, **1998**, 252, 17-33		38
427	PD-L1 assessment in urothelial carcinoma: a practical approach. *Annals of Translational Medicine*, **2019**, 7, 690	3.2	38
426	Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. *Human Pathology*, **2013**, 44, 2227-33	3.7	37

425	Histopathological findings after treatment of prostate cancer using high-intensity focused ultrasound (HIFU). *Prostate*, **2010**, 70, 1196-200	4.2	37
424	Downregulation of Fc gamma receptor IIIA alpha (CD16-II) on natural killer cells induced by anti-CD16 mAb is independent of protein tyrosine kinases and protein kinase C. *Cellular Immunology*, **1994**, 158, 208-17	4.4	37
423	Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. *European Urology*, **2009**, 56, 105-12	10.2	36
422	Pleomorphic giant cell carcinoma of the urinary bladder. *Human Pathology*, **2009**, 40, 1461-6	3.7	36
421	Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. *Cancer*, **2008**, 112, 636-44	6.4	36
420	Utility of whole slide imaging and virtual microscopy in prostate pathology. *Apmis*, **2012**, 120, 298-304	3.4	35
419	Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists. *Annals of Diagnostic Pathology*, **2014**, 18, 333-42	2.2	35
418	PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody. *Journal of Clinical Pathology*, **2012**, 65, 254-6	3.9	35
417	The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. *Future Oncology*, **2011**, 7, 519-41	3.6	35
416	Microcystic urothelial carcinoma: morphology, immunohistochemistry and clinical behaviour. *Histopathology*, **2014**, 64, 872-9	7.3	34
415	Prostatic adenocarcinoma with glomeruloid features. *Human Pathology*, **1998**, 29, 543-6	3.7	34
414	Identification of PMF1 methylation in association with bladder cancer progression. *Clinical Cancer Research*, **2008**, 14, 8236-43	12.9	34
413	BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma. *Cancer Letters*, **2007**, 250, 292-9	9.9	34
412	Laser capture microdissection in the genomic and proteomic era: targeting the genetic basis of cancer. *International Journal of Clinical and Experimental Pathology*, **2008**, 1, 475-88	1.4	34
411	Urothelial lesions with inverted growth patterns: histogenesis, molecular genetic findings, differential diagnosis and clinical management. *BJU International*, **2011**, 107, 532-7	5.6	33
410	Ectopic prostatic tissue: histogenesis and histopathological characteristics. *Histopathology*, **2011**, 58, 750-8	7.3	33
409	Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. *Expert Review of Anticancer Therapy*, **2010**, 10, 843-64	3.5	33
408	Search for residual prostate cancer on pT0 radical prostatectomy after positive biopsy. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2007**, 450, 371-8	5.1	33

407	Pleomorphic giant cell carcinoma of the prostate. *Archives of Pathology and Laboratory Medicine*, **2005**, 129, 683-5	5	33
406	**2012**,		33
405	Handling and reporting of nephrectomy specimens for adult renal tumours: a survey by the European Network of Uropathology. *Journal of Clinical Pathology*, **2012**, 65, 106-13	3.9	32
404	Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. *Modern Pathology*, **2007**, 20, 175-82	9.8	32
403	The Identification of Immunological Biomarkers in Kidney Cancers. *Frontiers in Oncology*, **2018**, 8, 456	5.3	32
402	Hypermethylation of tumor-suppressor gene CpG islands in small-cell carcinoma of the urinary bladder. *Modern Pathology*, **2008**, 21, 355-62	9.8	31
401	Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. *American Journal of Clinical Pathology*, **2004**, 122, 444-52	1.9	31
400	Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. *World Journal of Urology*, **2019**, 37, 107-114	4	30
399	Unique clinicopathologic and molecular characteristics of urinary bladder tumors in children and young adults. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 414-26	2.8	30
398	An interobserver reproducibility study on invasiveness of bladder cancer using virtual microscopy and heatmaps. *Histopathology*, **2013**, 63, 756-66	7.3	30
397	Flat urothelial carcinoma in situ of the bladder with glandular differentiation. *Human Pathology*, **2011**, 42, 1653-9	3.7	30
396	Prostate carcinoma II: prognostic factors in prostate needle biopsies. *BJU International*, **2006**, 97, 492-7	5.6	30
395	Unclassified renal cell carcinoma: a report of 56 cases. *BJU International*, **2012**, 110, 786-93	5.6	29
394	The origin of prostate metastases: emerging insights. *Cancer and Metastasis Reviews*, **2015**, 34, 765-73	9.6	28
393	Novel markers of squamous differentiation in the urinary bladder. *Human Pathology*, **2013**, 44, 1989-97	3.7	28
392	Handling and reporting of orchidectomy specimens with testicular cancer: areas of consensus and variation among 25 experts and 225 European pathologists. *Histopathology*, **2015**, 67, 313-24	7.3	28
391	Small cell carcinoma of the urinary bladder. *Histology and Histopathology*, **2010**, 25, 217-21	1.4	28
390	Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?. *BJU International*, **2009**, 103, 1058-63	5.6	27

389	Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications. *Cells*, **2020**, 9,	7.9	26
388	Mixed epithelial and stromal tumors of the kidney: evidence for a single cell of origin with capacity for epithelial and stromal differentiation. *American Journal of Surgical Pathology*, **2011**, 35, 1114-22	6.7	26
387	Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2014**, 1846, 630-7	11.2	25
386	Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Uropathology (ENUP). *Histopathology*, **2011**, 58, 579-85	7.3	25
385	Evidence for transformation of fibroadenoma of the breast to malignant phyllodes tumor. *Applied Immunohistochemistry and Molecular Morphology*, **2009**, 17, 345-50	1.9	25
384	Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis. *Prostate*, **2008**, 68, 919-23	4.2	25
383	Prostate carcinoma I: prognostic factors in radical prostatectomy specimens and pelvic lymph nodes. *BJU International*, **2006**, 97, 485-91	5.6	25
382	Is There a Role for Immunotherapy in Prostate Cancer?. *Cells*, **2020**, 9,	7.9	25
381	Tp53 and its potential therapeutic role as a target in bladder cancer. *Expert Opinion on Therapeutic Targets*, **2017**, 21, 401-414	6.4	24
380	Cystic partially regressed clear cell renal cell carcinoma: a potential mimic of multilocular cystic renal cell carcinoma. *Histopathology*, **2013**, 63, 767-79	7.3	24
379	The clinical and therapeutic implications of cancer stem cell biology. *Expert Review of Anticancer Therapy*, **2011**, 11, 1131-43	3.5	24
378	Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. *Human Pathology*, **2009**, 40, 211-7	3.7	24
377	alpha-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer. *American Journal of Clinical Pathology*, **2007**, 128, 657-66	1.9	24
376	Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice. *Current Drug Metabolism*, **2017**, 18, 712-722	3.5	24
375	TERT Promoter Mutations Occur Frequently in Urothelial Papilloma and Papillary Urothelial Neoplasm of Low Malignant Potential. *European Urology*, **2017**, 71, 497-498	10.2	23
374	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. *Clinical Drug Investigation*, **2019**, 39, 503-519	3.2	23
373	Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. *Molecular Carcinogenesis*, **2015**, 54, 900-7	5	22
372	Immunohistochemical evaluation of global DNA methylation and histone acetylation in papillary urothelial neoplasm of low malignant potential. *International Journal of Immunopathology and Pharmacology*, **2008**, 21, 615-23	3	22

371	Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. *Journal of Clinical Pathology*, **2016**, 69, 852-7	3.9	22
370	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. *Cancers*, **2019**, 11,	6.6	21
369	2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections. *European Urology Supplements*, **2009**, 8, 453-457	0.9	21
368	Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. *European Urology*, **2007**, 52, 1682-9	10.2	21
367	Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uropathology and the Uropathology Working Group. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2004**, 445, 103-10	5.1	21
366	Inflammatory pseudotumor of the urinary bladder. A clinicopathological analysis of two cases. *Urologia Internationalis*, **1995**, 55, 173-6	1.9	21
365	Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. *Current Drug Metabolism*, **2017**, 18, 700-711	3.5	21
364	Oncotargets in different renal cancer subtypes. *Current Drug Targets*, **2015**, 16, 125-35	3	21
363	Lymphoepithelioma-like carcinoma of the upper urinary tract. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2017**, 470, 703-709	5.1	20
362	The Human Microbiota and Prostate Cancer: Friend or Foe?. *Cancers*, **2019**, 11,	6.6	20
361	Is atypical adenomatous hyperplasia of the prostate a precursor lesion?. *Prostate*, **2011**, 71, 1746-51	4.2	20
360	Bladder treatment. Immunotherapy and chemotherapy. *Urologic Clinics of North America*, **1999**, 26, 535-54	2.9	20
359	Prognostic factors in survival of bladder cancer. *Cancer*, **1992**, 70, 799-807	6.4	20
358	Sclerosing adenosis of the prostate. Histologic features in needle biopsy specimens. *Archives of Pathology and Laboratory Medicine*, **2003**, 127, e14-6	5	20
357	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. *Cells*, **2019**, 8,	7.9	20
356	Large cell undifferentiated carcinoma of the urinary bladder. *Pathology*, **2010**, 42, 364-8	1.6	19
355	Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer. *Urology*, **2009**, 74, 385-90	1.6	19
354	Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation. *International Journal of Immunopathology and Pharmacology*, **2010**, 23, 511-22	3	19

353	Lymphatic vessel density in radical prostatectomy specimens. *Human Pathology*, **2008**, 39, 610-5	3.7	19
352	T1 high-grade bladder carcinoma outcome: the role of p16, topoisomerase-II, survivin, and E-cadherin. *Human Pathology*, **2016**, 57, 78-84	3.7	19
351	TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract. *Future Oncology*, **2017**, 13, 705-714	3.6	18
350	Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2019**, 475, 445-455	5.1	18
349	Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma. *European Urology Focus*, **2018**, 4, 880-888	5.1	18
348	FGFR3 and Cyclin D3 as urine biomarkers of bladder cancer recurrence. *Biomarkers in Medicine*, **2016**, 10, 243-53	2.3	18
347	Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. *Frontiers in Oncology*, **2018**, 8, 221	5.3	18
346	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. *Cancer Treatment Reviews*, **2018**, 68, 80-85	14.4	18
345	Adult primary paratesticular mesenchymal tumors with emphasis on a case presentation and discussion of spermatic cord leiomyosarcoma. *Diagnostic Pathology*, **2014**, 9, 90	3	18
344	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. *Cancer Treatment Reviews*, **2015**, 41, 614-22	14.4	18
343	Prostate needle biopsy processing: a survey of laboratory practice across Europe. *Journal of Clinical Pathology*, **2013**, 66, 120-3	3.9	18
342	Solitary fibrous tumour of the prostate identified on needle biopsy. *European Urology*, **2009**, 56, 564-7	10.2	18
341	Lymphoepithelioma-like carcinoma of the prostate. *Human Pathology*, **2009**, 40, 982-7	3.7	18
340	Virilizing mature ovarian cystic teratomas. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **1997**, 431, 149-51	5.1	18
339	Pathology of prostate cancer and focal therapy ('male lumpectomy'). *Anticancer Research*, **2009**, 29, 5155-61	2.5	18
338	Iatrogenic changes in the urinary tract. *Histopathology*, **2017**, 70, 10-25	7.3	17
337	KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. *Histopathology*, **2012**, 61, 1036-42	7.3	17
336	Long Non-coding RNAs in Prostate Cancer with Emphasis on Second Chromosome Locus Associated with Prostate-1 Expression. *Frontiers in Oncology*, **2017**, 7, 305	5.3	17

335	Ultrastructure of prostatic intraepithelial neoplasia. *Prostate*, **1997**, 33, 32-7	4.2	17
334	Apoptotic and proliferation indexes in primary superficial bladder tumors. *Cancer Letters*, **2006**, 242, 266-72	9.9	17
333	Spectrum of Cystic Epithelial Tumors of the Prostate: Most Cystadenocarcinomas Are Ductal Type With Intracystic Papillary Pattern. *American Journal of Surgical Pathology*, **2016**, 40, 886-95	6.7	17
332	RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. *Journal of Clinical Pathology*, **2019**, 72, 135-139	3.9	17
331	Prostate cancer: from Gleason scoring to prognostic grade grouping. *Expert Review of Anticancer Therapy*, **2016**, 16, 433-40	3.5	16
330	Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterations. *Histopathology*, **2015**, 67, 20-38	7.3	16
329	Targeting fibroblast growth factor receptor (FGFR) pathway in renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2015**, 15, 1367-9	3.5	16
328	Human papillomavirus is not an etiologic agent of urothelial inverted papillomas. *American Journal of Surgical Pathology*, **2013**, 37, 1223-8	6.7	16
327	Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. *Oncotarget*, **2017**, 8, 54096-54105	3.3	16
326	The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	16
325	Emerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsy. *Cancers*, **2019**, 11,	6.6	15
324	Immunohistochemical and molecular characterizations in urothelial carcinoma of bladder in patients less than 45 years. *Journal of Cancer*, **2017**, 8, 323-331	4.5	15
323	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. *Immunotherapy*, **2019** , 11, 1507-1521	3.8	15
322	Seminal vesicle intraepithelial neoplasia versus basal cell hyperplasia in a seminal vesicle. *European Urology*, **2014**, 66, 623-7	10.2	15
321	Clear cell renal cell carcinoma (ccRCC) with hemangioblastoma-like features: a previously unreported pattern of ccRCC with possible clinical significance. *European Urology*, **2014**, 66, 806-10	10.2	15
320	The spectrum of morphology in non-neoplastic prostate including cancer mimics. *Histopathology*, **2012**, 60, 41-58	7.3	15
319	Telomere shortening distinguishes inverted urothelial neoplasms. *Histopathology*, **2013**, 62, 595-601	7.3	15
318	Atypical adenomatous hyperplasia of prostate lacks TMPRSS2-ERG gene fusion. *American Journal of Surgical Pathology*, **2013**, 37, 1550-4	6.7	15

317	Cyclin D3 gene amplification in bladder carcinoma in situ. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2010**, 457, 555-61	5.1	15
316	Clonal origin of multifocal hepatocellular carcinoma. *Cancer*, **2010**, 116, 4078-85	6.4	15
315	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. *Frontiers in Oncology*, **2018**, 8, 397	5.3	15
314	P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications. *Anticancer Research*, **2005**, 25, 2001-4	2.3	15
313	Circulating Tumor Cells in Renal Cell Carcinoma: Recent Findings and Future Challenges. *Frontiers in Oncology*, **2019**, 9, 228	5.3	14
312	Inherited forms of bladder cancer: a review of Lynch syndrome and other inherited conditions. *Future Oncology*, **2018**, 14, 277-290	3.6	14
311	Molecular characteristics of urothelial neoplasms in children and young adults: a subset of tumors from young patients harbors chromosomal abnormalities but not FGFR3 or TP53 gene mutations. *Modern Pathology*, **2014**, 27, 1540-8	9.8	14
310	Expression of prostate stem cell antigen in high-grade prostatic intraepithelial neoplasia and prostate cancer. *Histopathology*, **2010**, 57, 572-9	7.3	14
309	Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer. *International Journal of Immunopathology and Pharmacology*, **2009**, 22, 755-62	3	14
308	Atypical adenomatous hyperplasia (adenosis) of the prostate: DNA ploidy analysis and immunophenotype. *International Journal of Surgical Pathology*, **2005**, 13, 167-73	1.2	14
307	T-zone histiocytes and recurrence of papillary urothelial bladder carcinoma. *Urologia Internationalis*, **1989**, 44, 205-9	1.9	14
306	Bladder cancer: molecular determinants of personalized therapy. *Current Drug Targets*, **2015**, 16, 115-243		14
305	Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers. *Expert Review of Molecular Diagnostics*, **2020**, 20, 231-243	3.8	14
304	Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. *Cancers*, **2019**, 12,	6.6	14
303	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. *European Urology*, **2016**, 69, 186-90	10.2	13
302	Solitary fibrous tumour of the genitourinary tract: a clinicopathological study of 11 cases and their association with the - fusion gene. *Journal of Clinical Pathology*, **2017**, 70, 508-514	3.9	13
301	Clinicopathologic analysis of upper urinary tract carcinoma with variant histology. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2020**, 477, 111-120	5.1	13
300	Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. *Expert Review of Molecular Diagnostics*, **2018**, 18, 645-655	3.8	13

299	The pathology of bladder cancer: An update on selected issues. *BJU International*, **2006**, 98, 1161-5	5.6	13
298	Histopathology reporting of prostate needle biopsies. 2005 update. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2006**, 449, 1-13	5.1	13
297	Evaluation of prognostic factors in radical prostatectomy specimens with cancer. *Urologia Internationalis*, **2002**, 68, 209-15	1.9	13
296	Metabolic Alterations in Renal and Prostate Cancer. *Current Drug Metabolism*, **2016**, 17, 150-5	3.5	13
295	Pathology Imagebase-a reference image database for standardization of pathology. *Histopathology* , **2017**, 71, 677-685	7.3	12
294	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 303-9	2.8	12
293	Primary renal osteosarcoma. *American Journal of Clinical Pathology*, **2014**, 141, 747-52	1.9	12
292	Pseudoangiosarcomatous urothelial carcinoma of the urinary bladder. *American Journal of Surgical Pathology*, **2014**, 38, 1251-9	6.7	12
291	Evidence for clonal fibroblast proliferation and autoimmune process in idiopathic retroperitoneal fibrosis. *Human Pathology*, **2012**, 43, 1875-80	3.7	12
290	Immunohistochemical expression of prostate tumor overexpressed 1 in cystoprostatectomies with incidental and insignificant prostate cancer. Further evidence for field effect in prostatic carcinogenesis. *Human Pathology*, **2011**, 42, 1931-6	3.7	12
289	Handling of radical prostatectomy specimens: total embedding with whole mounts, with special reference to the Ancona experience. *Histopathology*, **2011**, 59, 1006-10; author reply 1010-1	7.3	12
288	Nest-like features in bladder, simulating the nested variant of urothelial carcinoma. *International Journal of Surgical Pathology*, **2011**, 19, 11-9	1.2	12
287	2005 update on pathology of prostate biopsies with cancer. *European Urology*, **2006**, 49, 441-7	10.2	12
286	Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months. *Journal of Clinical Pathology*, **2007**, 60, 443-6	3.9	12
285	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. *Current Drug Targets*, **2016**, 17, 771-6	3	12
284	Variants of Bladder Cancer: The Pathologist's Point of View. *European Urology Supplements*, **2017**, 16, 210-222	0.9	11
283	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. *Cancers*, **2019**, 11,	6.6	11
282	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. *Seminars in Cancer Biology*, **2018**, 52, 216-227	12.7	11

281	Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate: additional evidence linking (AAH) to adenocarcinoma. *Cellular Oncology (Dordrecht)*, **2013**, 36, 37-42	7.2	11
280	Pathological definition and difficulties in assessing positive margins in radical prostatectomy specimens. *BJU International*, **2009**, 103, 286-8	5.6	11
279	Association of human herpesvirus type 6 DNA with human bladder cancer. *Cancer Letters*, **2005**, 230, 20-4	9.9	11
278	The expression patterns of p53 and p16 and an analysis of a possible role of HPV in primary adenocarcinoma of the urinary bladder. *PLoS ONE*, **2014**, 9, e95724	3.7	11
277	Neoplasms of the urinary bladder **2008**, 258-351		11
276	Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC. *Journal of Clinical Pathology*, **2020**, 73, 695-696	3.9	11
275	Morphological and molecular profiles and pathways in bladder neoplasms. *Anticancer Research*, **2008**, 28, 2893-900	2.3	11
274	Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer. *Apmis*, **2019**, 127, 545-553	3.4	10
273	Microbiome and Cancers, With Focus on Genitourinary Tumors. *Frontiers in Oncology*, **2019**, 9, 178	5.3	10
272	Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. *Archives of Pathology and Laboratory Medicine*, **2016**, 140, 501-2	5	10
271	Concomitant bladder cancer and prostate cancer: challenges and controversies. *Nature Reviews Urology*, **2017**, 14, 620-629	5.5	10
270	Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2015**, 467, 687-693	5.1	10
269	Renal cell carcinoma with rhabdoid features and loss of INI1 expression in an individual without sickle cell trait. *Pathology*, **2014**, 46, 653-5	1.6	10
268	Digital Biopsy with Fluorescence Confocal Microscope for Effective Real-time Diagnosis of Prostate Cancer: A Prospective, Comparative Study. *European Urology Oncology*, **2021**, 4, 784-791	6.7	10
267	Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. *World Journal of Urology*, **2017**, 35, 517-526	4	9
266	Iatrogenic pathology of the urinary bladder. *Seminars in Diagnostic Pathology*, **2018**, 35, 218-227	4.3	9
265	EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. *Modern Pathology*, **2014**, 27, 107-12	9.8	9
264	Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma. *Diagnostic Pathology*, **2013**, 8, 111	3	9

263	Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations. *Future Oncology*, **2013**, 9, 245-53	3.6	9
262	Words of wisdom: re: multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. *European Urology*, **2013**, 63, 400-1	10.2	9
261	Whole Slide Imaging of Large Format Histology in Prostate Pathology: Potential for Information Fusion. *Archives of Pathology and Laboratory Medicine*, **2017**, 141, 1460-1461	5	9
260	Urethral caruncle: a lesion related to IgG4-associated sclerosing disease?. *Journal of Clinical Pathology*, **2013**, 66, 559-62	3.9	9
259	Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer. *BJU International*, **2010**, 106, 1072-80	5.6	9
258	Genetic profiles in renal tumors. *International Journal of Urology*, **2010**, 17, 6-19	2.3	9
257	Decision support systems for morphology-based diagnosis and prognosis of prostate neoplasms: a methodological approach. *Cancer*, **2009**, 115, 3068-77	6.4	9
256	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. *Seminars in Diagnostic Pathology*, **2008**, 25, 232-44	4.3	9
255	Expression of P-glycoprotein and metallothionein in gastrointestinal stromal tumor and leiomyosarcomas. Clinical implications. *Pathology and Oncology Research*, **2007**, 13, 203-8	2.6	9
254	Genetic mutations in accordance with a low malignant potential tumour are not demonstrated in clear cell papillary renal cell carcinoma. *Journal of Clinical Pathology*, **2016**, 69, 547-50	3.9	9
253	Data set for the reporting of carcinoma of renal tubular origin: recommendations from the International Collaboration on Cancer Reporting (ICCR). *Histopathology*, **2019**, 74, 377-390	7.3	9
252	Liquid biopsy in the clinical management of bladder cancer: current status and future developments. *Expert Review of Molecular Diagnostics*, **2020**, 20, 255-264	3.8	9
251	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. *Expert Review of Molecular Diagnostics*, **2020**, 20, 141-150	3.8	9
250	Hypochromatic large urothelial cells in urine cytology are indicative of high grade urothelial carcinoma. *Apmis*, **2018**, 126, 705-709	3.4	9
249	Pathology of renal cell carcinoma: an update. *Analytical and Quantitative Cytopathology and Histopathology*, **2013**, 35, 61-76		9
248	Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance. *European Urology*, **2020**, 78, 478-481	10.2	8
247	Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer. *Cells*, **2020**, 9,	7.9	8
246	Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. *American Journal of Surgical Pathology*, **2018**, 42, e33-e43	6.7	8

245	Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma. *Expert Review of Anticancer Therapy*, **2018**, 18, 685-693	3.5	8
244	Re: epithelial-to-mesenchymal transition in renal neoplasms. *European Urology*, **2015**, 68, 736-7	10.2	8
243	Expression of OCT4 transcription factor in cutaneous neoplasia. *Applied Immunohistochemistry and Molecular Morphology*, **2007**, 15, 359-62	1.9	8
242	Evolution of extramedullary plasmacytoma in a patient with primary Sjgren's syndrome. *Arthritis and Rheumatism*, **1990**, 33, 150-1		8
241	Epigenetic Modifications and Modulators in Prostate Cancer. *Critical Reviews in Oncogenesis*, **2017**, 22, 439-450	1.3	8
240	An Overview of Emerging Immunotargets of Genitourinary Tumors. *Current Drug Targets*, **2016**, 17, 750-6	3	8
239	International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. *European Urology Focus*, **2021**,	5.1	8
238	Pathology and molecular updates in tumors of the prostate: towards a personalized approach. *Expert Review of Molecular Diagnostics*, **2017**, 17, 781-789	3.8	7
237	A contemporary series of renal masses with emphasis on recently recognized entities and tumors of low malignant potential: A report based on 624 consecutive tumors from a single tertiary center. *Pathology Research and Practice*, **2017**, 213, 804-808	3.4	7
236	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. *European Urology Supplements*, **2017**, 16, 309-315	0.9	7
235	Digital versus light microscopy assessment of surgical margin status after radical prostatectomy. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2018**, 472, 451-460	5.1	7
234	Total submission of lymphadenectomy tissues removed during radical prostatectomy for prostate cancer: possible clinical significance of large-format histology. *Human Pathology*, **2014**, 45, 2059-62	3.7	7
233	Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase. *International Journal of Immunopathology and Pharmacology*, **2012**, 25, 67-74	3	7
232	How much do you know about benign, preneoplastic, non-invasive and invasive neoplastic lesions of the urinary bladder classified according to the 2004 WHO scheme?. *Diagnostic Pathology*, **2011**, 6, 31	3	7
231	Clonality and TP53 mutation analysis of focal nodular hyperplasia of the liver. *American Journal of Clinical Pathology*, **2010**, 134, 65-70	1.9	7
230	Renal oncocytosis and multiple papillary adenomas with oncocytoma as dominant nodule coexisting with papillary carcinoma in a patient with diabetic glomerulosclerosis, acquired renal cystic disease and B cell lymphoma. *Apmis*, **2008**, 116, 934-8	3.4	7
229	Circulating Tumor Cells: A Reliable Biomarker for Prostate Cancer Treatment Assessment?. *Current Drug Metabolism*, **2017**, 18, 692-699	3.5	7
228	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. *Current Drug Metabolism*, **2019**, 20, 305-312	3.5	7

227	Emerging Immunotargets and Immunotherapies in Prostate Cancer. *Current Drug Targets*, **2016**, 17, 777-82	3	7
226	Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. *Expert Review of Anticancer Therapy*, **2020**, 20, 755-763	3.5	7
225	Towards a new WHO classification of renal cell tumor: what the clinician needs to know-a narrative review. *Translational Andrology and Urology*, **2021**, 10, 1506-1520	2.3	7
224	Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing. *Cancers*, **2021**, 13,	6.6	7
223	Urothelial dysplasia of the bladder: diagnostic features and clinical significance. *Analytical and Quantitative Cytopathology and Histopathology*, **2013**, 35, 121-9		7
222	Small cell carcinoma of the prostate: molecular basis and clinical implications. *Histology and Histopathology*, **2015**, 30, 413-24	1.4	7
221	Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter. *Therapeutic Advances in Urology*, **2019**, 11, 1756287218815372	3.2	6
220	Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections. *Human Pathology*, **2014**, 45, 745-52	3.7	6
219	Lymphocytic vasculitis of the prostate transition zone. *BJU International*, **2012**, 110, 1775-80	5.6	6
218	Re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and Seminal Vesicles as Observed in Virtual Whole-mount Histologic Slides. *European Urology*, **2017**, 71, e73-e75	10.2	6
217	Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize?. *Diagnostic Pathology*, **2014**, 9, 190	3	6
216	Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis. *International Journal of Immunopathology and Pharmacology*, **2011**, 24, 489-97	3	6
215	A contemporary update on pathology reporting for urinary bladder cancer. *International Journal of Immunopathology and Pharmacology*, **2012**, 25, 565-71	3	6
214	The dilemma of multiorgan donors with high serum PSA--a pathologist's proposal. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2006**, 449, 273-6	5.1	6
213	Immunohistochemical Expression and Localization of Somatostatin Receptor Subtypes in Androgen Ablated Prostate Cancer. *Analytical Cellular Pathology*, **2010**, 33, 27-36	3.4	6
212	Liquid Biopsies in the Management of Bladder Cancer: Next-Generation Biomarkers for Diagnosis, Surveillance, and Treatment-Response Prediction. *Critical Reviews in Oncogenesis*, **2017**, 22, 389-401	1.3	6
211	Prognostic microRNAs in upper tract urothelial carcinoma: multicenter and international validation study. *Oncotarget*, **2017**, 8, 51522-51529	3.3	6
210	Emerging Immunotargets in Bladder Cancer. *Current Drug Targets*, **2016**, 17, 757-70	3	6

209	Predicting future cancer burden in the United States by artificial neural networks. *Future Oncology*, **2021**, 17, 159-168	3.6	6
208	Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy. *Expert Review of Molecular Diagnostics*, **2018**, 18, 1021-1028	3.8	6
207	Human papillomavirus (HPV)-induced neoplasia in the urinary bladder: a missing link?. *Histology and Histopathology*, **2016**, 31, 595-600	1.4	6
206	Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?. *European Urology*, **2019**, 76, e69-e72	10.2	5
205	Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report. *Human Pathology*, **2015**, 46, 1040-4	3.7	5
204	Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur Urol 2015;68:912-4. *European Urology*, **2016**, 70, e72-4	10.2	5
203	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. *Future Oncology*, **2018**, 14, 2559-2564	3.6	5
202	Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy). *Pathology Research and Practice*, **2017**, 213, 1078-1081	3.4	5
201	TMPRSS2-ERG gene fusion is rare compared to PTEN deletions in stage T1a prostate cancer. *Molecular Carcinogenesis*, **2017**, 56, 814-820	5	5
200	Urinary bladder xanthoma: a multi-institutional series of 17 cases. *Histopathology*, **2015**, 67, 255-61	7.3	5
199	Present and future of personalized medicine in adult genitourinary tumors. *Future Oncology*, **2015**, 11, 1381-8	3.6	5
198	Words of wisdom. Re: Antibody-drug conjugates targeting prostate-specific membrane antigen. *European Urology*, **2014**, 66, 1190-3	10.2	5
197	Combined handling of prostate base/bladder neck and seminal vesicles in radical prostatectomy specimens: our approach with the whole mount technique. *Histopathology*, **2013**, 63, 431-5	7.3	5
196	Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. *Cellular Oncology (Dordrecht)*, **2011**, 34, 235-43	7.2	5
195	Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview. *Current Drug Targets*, **2015**, 16, 96-102	3	5
194	pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2020**, 477, 3-16	5.1	5
193	Stage T1 bladder cancer: diagnostic criteria and pitfalls. *Pathology*, **2021**, 53, 67-85	1.6	5
192	Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. *Critical Reviews in Oncology/Hematology*, **2018**, 131, 1-6	7	5

191	Prostate cancer grading in 2018: limitations, implementations, cribriform morphology, and biological markers. *International Journal of Biological Markers*, **2018**, 33, 331-334	2.8	5
190	Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets. *Future Oncology*, **2017**, 13, 1105-1114	3.6	4
189	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. *European Urology Supplements*, **2017**, 16, 301-308	0.9	4
188	MYB-NFIB gene fusion in prostatic basal cell carcinoma: clinicopathologic correlates and comparison with basal cell adenoma and florid basal cell hyperplasia. *Modern Pathology*, **2019**, 32, 1666-1674	9.8	4
187	Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. *Future Oncology*, **2015**, 11, 2711-2719	3.6	4
186	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. *Cells*, **2020**, 9,	7.9	4
185	Intratumoural heterogeneity may hinder precision medicine strategies in patients with clear cell renal cell carcinoma. *Journal of Clinical Pathology*, **2018**, 71, 467-471	3.9	4
184	Macrocryosectioning and complete sampling of the prostate in a potential multiorgan donor candidate. *Journal of Clinical Pathology*, **2007**, 60, 951-2	3.9	4
183	Radical prostatectomy specimen processing: A critical appraisal of sampling methods. *Current Diagnostic Pathology*, **2007**, 13, 490-498		4
182	Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer. *Analytical Cellular Pathology*, **2010**, 33, 27-36	3.4	4
181	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. *Current Drug Targets*, **2020**, 21, 1463-1475	3	4
180	Designing novel immunocombinations in metastatic renal cell carcinoma. *Immunotherapy*, **2020**, 12, 1257-1268	3.8	4
179	Multiple and bilateral kidney tumors with clear cells of three different histotypes: A case report with clinicopathologic and molecular study. *Apmis*, **2016**, 124, 619-623	3.4	4
178	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. *Expert Review of Molecular Diagnostics*, **2020**, 20, 207-217	3.8	4
177	Molecular pathology of urothelial carcinoma. *Human Pathology*, **2021**, 113, 67-83	3.7	4
176	Active surveillance for low-risk prostate cancer. *Anticancer Research*, **2010**, 30, 3683-92	2.3	4
175	Considerations for standardizing predictive molecular pathology for cancer prognosis. *Expert Review of Molecular Diagnostics*, **2017**, 17, 47-55	3.8	3
174	Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View. *European Urology Supplements*, **2017**, 16, 223-231	0.9	3

173	Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2019**, 475, 735-744	5.1	3
172	Re: Multi-institutional Re-evaluation of Prognostic Factors in Chromophobe Renal Cell Carcinoma: Proposal of a Novel Two-tiered Grading Scheme. *European Urology*, **2020**, 78, 114-116	10.2	3
171	Re: Isabel Rauscher, Charlotte Düwel, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. Eur Urol 2018;73:656-61: Clinical Significance of Prostate-specific Membrane Antigen Immunohistochemistry and Role of the Uropathologists. *European Urology*, **2018**, 74, e141-e144	10.2	3
170	A low grade PIN-like neoplasm of the transition zone immunohistochemically negative for basal cell markers: a possible example of low grade adenocarcinoma with stratified epithelium. *Pathology*, **2014**, 46, 88-91	1.6	3
169	Müllerian Adenosarcoma of the Urinary Bladder: Clinicopathologic and Immunohistochemical Features With Novel Genetic Aberrations. *Clinical Genitourinary Cancer*, **2017**, 15, e1007-e1014	3.3	3
168	Somatostatin receptor expression in prostate carcinoma: the urological pathologist's role in the era of personalised medicine. *Pathology*, **2013**, 45, 93-6	1.6	3
167	Synchronous metastasis from lobular carcinoma and primary carcinoma of the endometrium in a patient after tamoxifen therapy. *International Journal of Gynecological Pathology*, **2013**, 32, 66-70	3.2	3
166	The Gleason grading system: where are we now?. *Diagnostic Histopathology*, **2011**, 17, 419-427	0.7	3
165	Vasculitis Involving the Prostate **1996**, 1, 70-73		3
164	Urinary Biomarkers for Prostate Cancer. *Current Drug Metabolism*, **2017**, 18, 723-726	3.5	3
163	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. *Current Drug Targets*, **2020**, 21, 1664-1671	3	3
162	Implications of Cancer Stem Cells for Cancer Therapy **2009**, 255-262		3
161	Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma. *Asian Journal of Andrology*, **2011**, 13, 242-7	2.8	3
160	Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. *European Urology Focus*, **2021**, 7, 955-963	5.1	3
159	Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications. *Modern Pathology*, **2021**, 34, 1384-1391	9.8	3
158	Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
157	Dataset for the reporting of renal biopsy for tumour: recommendations from the International Collaboration on Cancer Reporting (ICCR). *Journal of Clinical Pathology*, **2019**, 72, 573-578	3.9	3
156	Data Set for the Reporting of Carcinoma of the Renal Pelvis and Ureter-Nephroureterectomy and Ureterectomy Specimens: Recommendations From the International Collaboration on Cancer Reporting (ICCR). *American Journal of Surgical Pathology*, **2019**, 43, e1-e12	6.7	3

155	Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589-97. Eur Urol 2018;74:525-6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on	10.2	3
154	Histopathologic challenges: The second OPINION issue. *European Journal of Surgical Oncology*, **2019**, 45, 12-15	3.6	3
153	Prostate cancer pathology: What has changed in the last 5 years. *Urologia*, **2020**, 87, 3-10	1.2	3
152	Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One. *European Urology Oncology*, **2021**, 4, 331-333	6.7	3
151	Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review. *European Urology Oncology*, **2021**, 4, 558-569	6.7	3
150	An update on investigational therapies that target STAT3 for the treatment of cancer. *Expert Opinion on Investigational Drugs*, **2021**, 30, 245-251	5.9	3
149	Workgroup 5: Assessment of prostate carcinoma in core needle biopsy--Definition of minimal criteria for the diagnosis of cancer in biopsy material **1996**, 78, 376		3
148	Chromosomal abnormalities in macroscopically normal urothelium in patients with bladder pT1 and pT2a urothelial carcinoma: a fluorescence in situ hybridization study and correlation with histologic features **2005**, 27, 143-51		3
147	The European Network of Uropathology: a novel mechanism for communication between pathologists **2009**, 31, 90-5		3
146	Cell proliferation and apoptosis in prostate needle biopsies with adenocarcinoma Gleason score 6 or 7 **2012**, 34, 61-5		3
145	Re: Kenneth A. Iczkowski's Letter to the Editor re: Re: Rodolfo Montironi, Silvia Gasparrini, Roberta Mazzucchelli, et al's Letter to the Editor re: Karim A. Touijer, James A. Eastham. The Sentinel Lymph Node Concept and Novel Approaches in Detecting Lymph Node Metastasis in Prostate Cancer. Eur Urol 2016;70:738-9: Sentinel Lymph Nodes in Adipose Tissue Surrounding the Prostate Gland and	10.2	2
144	Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View. *European Urology Supplements*, **2017**, 16, 232-240	0.9	2
143	Molecular evidence supporting the precursor nature of atypical adenomatous hyperplasia of the prostate. *Molecular Carcinogenesis*, **2019**, 58, 1272-1278	5	2
142	Rare Tumors and Tumor-like Conditions in Urological Pathology **2015**,		2
141	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. *Cells*, **2020**, 9,	7.9	2
140	A Multiplex Test Assessing and in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
139	Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule. *Human Pathology*, **2019**, 93, 6-15	3.7	2
138	Pathology of flat bladder lesions with emphasis on putative precursors. *Diagnostic Histopathology*, **2013**, 19, 355-365	0.7	2

137	Immunotherapy in genitourinary cancers: where are we going?. *Expert Review of Precision Medicine and Drug Development*, **2017**, 2, 73-78	1.6	2
136	Pathological issues in biopsy specimens of men with prostate cancer eligible for active surveillance. *Archivio Italiano Di Urologia Andrologia*, **2014**, 86, 314-8	1.6	2
135	Bladder cancer: Normal cystoscopy, malignant cytology in NMIBC: why biopsy?. *Nature Reviews Urology*, **2014**, 11, 550-1	5.5	2
134	Bladder Cancer: General Features **2012**, 137-159		2
133	Grading of Bladder Cancer **2012**, 161-191		2
132	Rare Lesions and Tumors of the Urinary Bladder. Selected Issues. *Tumori*, **2012**, 98, 274-277	1.7	2
131	Cervical-type squamous metaplasia and myoepithelial cell differentiation in stromal tumor of the prostate. *American Journal of Surgical Pathology*, **2011**, 35, 1752-4	6.7	2
130	Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters. *European Urology*, **2009**, 56, 846-7	10.2	2
129	Words of wisdom. Re: peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology. *European Urology*, **2010**, 58, 180-2	10.2	2
128	Urothelial Dysplasia and Its Mimics **2008**, 13, 149-153		2
127	Synchronous clear cell renal cell carcinoma and multilocular cystic renal cell neoplasia of low malignant potential: A clinico-pathologic and molecular study. *Pathology Research and Practice*, **2016**, 212, 471-4	3.4	2
126	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. *Expert Review of Cardiovascular Therapy*, **2019**, 17, 917-927	2.5	2
125	Contemporary update on pathology-related issues of adult renal neoplasms. *Analytical and Quantitative Cytopathology and Histopathology*, **2014**, 36, 1-8		2
124	Prostatic and urothelial metastasis in the same lymph node: a case report. *Analytical and Quantitative Cytopathology and Histopathology*, **2015**, 37, 139-43		2
123	Re: Umberto Leone Roberti Maggiore, Simone Ferrero, Massimo Candiani, et al. Bladder Endometriosis: A Systematic Review of Pathogenesis, Diagnosis, Treatment, Impact on Fertility, and Risk of Malignant Transformation. Eur Urol 2017;71:790-807. *European Urology*, **2017**, 72, e139-e141	10.2	1
122	Prospects for precision therapy of bladder urothelial carcinoma. *Expert Review of Precision Medicine and Drug Development*, **2017**, 2, 261-274	1.6	1
121	Dataset for reporting of carcinoma of the urethra (in urethrectomy specimens): recommendations from the International Collaboration on Cancer Reporting (ICCR). *Histopathology*, **2019**, 75, 453-467	7.3	1
120	Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol 2019;75:538-40. *European Urology*, **2019**, 75, e162-e163	10.2	1

119	PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness. *International Journal of Biological Markers*, **2020**, 35, 82-90	2.8	1
118	Renal Cell Carcinoma: genomic landscape and clinical implications. *Expert Review of Precision Medicine and Drug Development*, **2020**, 5, 95-100	1.6	1
117	Molecular diagnostics in uro-oncology. *Expert Review of Molecular Diagnostics*, **2020**, 20, 117-121	3.8	1
116	Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Sparing in Radical Prostatectomy. *European Urology*, **2018**, 73, 978-980	10.2	1
115	Intracardiac leiomyomatosis presenting as an intraoperative consultation. *Pathology Research and Practice*, **2016**, 212, 578-81	3.4	1
114	Words of wisdom. Re: "No pay, no play": the end of professional ethics in pathology?. *European Urology*, **2012**, 61, 424-5	10.2	1
113	Precise morphologic documentation with large-format histology of clinical findings in a bladder cancer patient. *European Urology*, **2013**, 64, 519-21	10.2	1
112	Prostate changes related to therapy: with special reference to hormone therapy. *Future Oncology*, **2014**, 10, 1873-86	3.6	1
111	Stage pT1 Urothelial Carcinoma **2012**, 193-215		1
110	Inflammatory and Infectious Conditions **2012**, 17-44		1
109	Urothelial Metaplasia and Hyperplasia **2012**, 45-70		1
108	Adenocarcinoma and Its Putative Precursors and Variants **2012**, 283-203		1
107	Urothelial Carcinoma in Situ **2012**, 113-136		1
106	Bladder Tumors with Inverted Growth **2012**, 383-398		1
105	Handling and Reporting of Bladder Specimens **2012**, 525-544		1
104	Squamous Cell Carcinoma and Other Squamous Lesions **2012**, 305-321		1
103	Treatment Effects **2012**, 507-523		1
102	Conceptual Evolution in Cancer Biology **2013**, 77-109		1

101	"No pay, no play" or from "defensive or passive pathology" to "active, clinically oriented pathology". *Archives of Pathology and Laboratory Medicine*, **2012**, 136, 1474-5; author reply 1475	5	1
100	Rare lesions and tumors of the urinary bladder. Selected issues. *Tumori*, **2012**, 98, 274-7	1.7	1
99	Pathology of tumors of the renal pelvis and ureter and the urethra **2007**, 235-242		1
98	Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. *Asian Journal of Andrology*, **2017**,	2.8	1
97	Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2019**, 71, 189-190	4.4	1
96	Molecular Characterization of Testicular Germ Cell Tumors Using Tissue Microdissection. *Methods in Molecular Biology*, **2021**, 2195, 31-47	1.4	1
95	The Pathology of Prostate Cancer **2010**, 45-83		1
94	Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States. *Translational Andrology and Urology*, **2021**, 10, 1562-1568	2.3	1
93	Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489-91. *European Urology*, **2021**, 79, e172-e173	10.2	1
92	Cysts and Epithelial Proliferations of the Testicular Collecting System **2016**, 171-189		1
91	Nonneoplastic Disorders of the Urinary Bladder **2020**, 195-229.e11		1
90	Neoplasms of the Urinary Bladder **2020**, 230-321.e19		1
89	Re: Alfonso Gîmez de Liaô Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. *European Urology*, **2021**, 79, e17-e19	10.2	1
88	Fluorescence In Situ Hybridization (FISH) Detection of Chromosomal 12p Anomalies in Testicular Germ Cell Tumors. *Methods in Molecular Biology*, **2021**, 2195, 49-63	1.4	1
87	Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 2015;68:912-4. *European Urology*, **2017**, 71, e27-e28	10.2	0
86	Histologic Variants of Urothelial Carcinoma **2012**, 239-281		0
85	Editorial comment on: Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. *European Urology*, **2009**, 55, 402	10.2	0
84	Reply to Josˆ. Lopž's Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen? Eur Urol 2009;56:272. *European Urology*, **2010**, 57, e22-e23	10.2	0

83	Editorial comment on: Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. *European Urology*, **2008**, 54, 843-4	10.2	0
82	Re: Aurlien Descazeaud, Marc Zerbib, Thierry Flam et al. Can pT0 stage of prostate cancer be predicted before radical prostatectomy? Eur Urol 2006;50:1248-53. *European Urology*, **2007**, 52, 294-5	10.2	0
81	T1 bladder carcinoma with variant histology: pathological features and clinical significance.. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2022**, 1	5.1	0
80	Paratesticular well-differentiated liposarcoma initially diagnosed as fibrous pseudotumour. *Indian Journal of Pathology and Microbiology*, **2020**, 63, S53-S55	0.6	0
79	Mesonephric (Wolffian-derived) Adenocarcinoma of the Female Urethra. *American Journal of Surgical Pathology*, **2021**, 45, 543-549	6.7	0
78	Narrative review of prostate cancer grading systems: will the Gleason scores be replaced by the Grade Groups?. *Translational Andrology and Urology*, **2021**, 10, 1530-1540	2.3	0
77	?? Prostate and Breast Pathology: Similarities and Differences **2019**, 155-170		0
76	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. *Translational Andrology and Urology*, **2021**, 10, 1581-1587	2.3	0
75	Artificial intelligence and prostate cancer: Advances and challenges. *Urologia*, **2021**, 3915603211062409	1.2	0
74	The International Society of Urological Pathology Consensus Conference regarding the classification, prognostic factors, staging, and immunohistochemical and molecular assessment of adult renal tumors. *Revista Espanola De Patologia*, **2015**, 48, 90-96	1.2	
73	Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871. *European Urology*, **2020**, 77, e122-e127	10.2	
72	In reply to: letter to the editor entitled: primary pure lymphoepithelioma-like carcinoma of the ureter. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2017**, 471, 561-562	5.1	
71	Reply to Jrme Verine's letter to the editor Re: Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng, Marina Scarpelli. Re: Multilocular cystic renal cell carcinoma with focus on clinical and pathobiological aspects. Eur Urol 2013;63:400-1. *European Urology*, **2013**, 63, e74-5	10.2	
70	Reply to Jrme Verine's letter to the editor Re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4-related disease in genitourinary organs: an emerging fibroinflammatory entity often misdiagnosed preoperatively as cancer. *European Urology*, **2013**, 64, e53-4	10.2	
69	Tumors of the Urinary Bladder **2013**, 85-100		
68	The Prostate and Seminal Vesicles **2015**, 195-310		
67	Polyps and Other Nonneoplastic Benign Conditions **2012**, 71-84		
66	Sarcomatoid Carcinoma (Carcinosarcoma) **2012**, 355-381		

65 Congenital Disorders and Pediatric Neoplasms **2012**, 399-422

64 Pathology of the Urachus **2012**, 567-579

63 Pathology of Renal Pelvis, Ureter, and Urethra **2012**, 581-608

62 Molecular Determinants of Tumor Recurrence **2012**, 609-622

61 Normal Anatomy and Histology **2012**, 1-16

60 Neuroendocrine Tumors **2012**, 323-353

59 Benign Epithelial Tumors **2012**, 85-97

58 Staging of Bladder Cancer **2012**, 217-237

57 Flat Urothelial Lesions with Atypia and Urothelial Dysplasia **2012**, 99-112

56 Lymphoid and Hematopoietic Tumors **2012**, 461-469

55 Soft Tissue Tumors **2012**, 423-459

54 Urothelial Carcinoma Following Augmentation Cystoplasty **2012**, 471-484

53 Other Rare Tumors **2012**, 485-495

52 Secondary Tumors **2012**, 497-505

51 Diagnostic Immunohistochemistry **2012**, 545-565

50 Urine-based Biomarkers **2012**, 655-678

49 Tissue-based Biomarkers **2012**, 679-706

48 Molecular Pathology of Bladder Cancer **2012**, 707-733

47	Reply to Kiril Trpkov, Asli Yilmaz Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patients Pathology and Clinical Reports. Eur Urol 2010;58:369 3. *European Urology*, **2011**, 59, e7-e8	10.2
46	Editorial comment on: validation of the contemporary epstein criteria for insignificant prostate cancer in European men. *European Urology*, **2008**, 54, 1311-2	10.2
45	Editorial comment on: comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. *European Urology*, **2008**, 54, 380-1	10.2
44	Prostatic Acinar Adenocarcinoma, Sarcomatoid Variant. *Encyclopedia of Pathology*, **2020**, 319-322	0
43	Renal Cell Carcinoma, Unclassified. *Encyclopedia of Pathology*, **2020**, 342-344	0
42	Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles.. *Pathology Research and Practice*, **2021**, 229, 153737	3.4
41	What's the future in uropathology. *Urologia*, **2021**, 88, 265-266	1.2
40	Urinary Bladder **2006**, 1175-1218	
39	Familial Cancer Syndromes **2008**, 449-466	
38	Bladder Cloacal Extrophy. *Encyclopedia of Pathology*, **2019**, 1-3	0
37	Staging and Reporting of Renal Cell Carcinomas **2020**, 423-436	
36	Specimen Handling: Radical and Partial Nephrectomy Specimens **2020**, 411-422	
35	Bladder Cloacal Extrophy. *Encyclopedia of Pathology*, **2020**, 20-22	0
34	Urothelial Carcinoma, Lymphoepithelioma-Like Type. *Encyclopedia of Pathology*, **2020**, 477-479	0
33	Pathology of the Benign and Malignant Diseases of the Prostate **2020**, 1-12	
32	Urothelial Carcinoma, Lipid-Rich Type. *Encyclopedia of Pathology*, **2020**, 475-477	0
31	Lipomatous hypertrophy of the cardiac interatrial septum. *American Journal of Forensic Medicine and Pathology*, **1997**, 18, 206-7	1
30	Tumors and Tumor-Like Conditions of Urinary Bladder, Renal Pelvis, Ureter and Urethra **2015**, 63-194	

29	Renal Tumors and Tumor-Like Conditions **2015**, 1-61	
28	Urinary Bladder **2016**, 1681-1735	
27	Renal Pelvis, Ureter, and Urethra **2016**, 1737-1750	
26	Bone Homing and Metastasis **2017**, 25-32	
25	Renal Pelvis, Ureter, and Urethra **2011**, 1567-1579	
24	Urinary Bladder **2011**, 1515-1565	
23	Role of Pathology in the Multidisciplinary Management of Patients with Prostate Cancer **2014**, 29-41	
22	Let us not forget about our past contributions to the field of prostatic neoplasms: To some extent what we value now was already there. *Pathology Research and Practice*, **2021**, 219, 153377	3.4
21	RE: Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer, by Jones TD and Cheng L, https://doi.org/10.1016/j.urolonc.2020.12.007 (Low grade papillary intra-urothelial neoplasia). *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 308-309	2.8
20	The Coronavirus Disease 2019 (COVID-19) Pandemic's Impact on Social Interaction in Pathology. *Archives of Pathology and Laboratory Medicine*, **2021**, 145, 1049-1050	5
19	Prostate cancer grading in 2016. *Minerva Urology and Nephrology*, **2017**, 69, 1-4	2.3
18	Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. Eur Urol 2015;68:542-3. *European Urology*, **2016**, 70, e69-70	10.2
17	Handling of the Surgical Specimen and Pathology Reporting of Penile Neoplasms **2016**, 275-280	
16	Handling of the Surgical Specimen and Pathology Reporting of Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis **2016**, 165-170	
15	?The Prostatic Utricle and Endometrioid Prostate Cancer **2019**, 123-127	
14	?? Cystic Lesions of the Prostate and Lower Genitourinary Tract versus Female Gynecologic Tract Lesions: Similarities and Differences **2019**, 128-139	
13	??Ectopic Prostatic Tissue **2019**, 145-149	
12	?? Clear Cell Tumors of the Kidney and the Gynecologic Tract **2019**, 173-188	

11	??Similarities and Differences in Neuroendocrine Tumors of the Male and Female Genital Tracts and Urinary Tract **2019**, 233-244	
10	?? Transitional Cell Tumors of the Bladder **2019**, 254-273	
9	?? Micropapillary Urothelial Carcinoma of the Bladder versus Gynecologic Tract Carcinomas with Micropapillary Features: Similarities and Differences **2019**, 278-282	
8	?? Pathology of the Female and Male Urethra **2019**, 285-303	
7	?? Müllerian Lesions of the Bladder: Endometriosis, Endosalpingiosis, Endocervicosis, and Müllerianosis **2019**, 304-309	
6	??Clear Cell Carcinoma of the Urinary Tract vs. Clear Cell Carcinoma of the Ovary: Similarities and Differences **2019**, 310-315	
5	??Cystic and Solid Tumors of the Urachus vs. Gynecologic Tract Tumors: Similarities and Differences **2019**, 316-330	
4	??Secondary Tumors of the Male and Female Genital Tracts and Urinary Tract: Similarities and Differences **2019**, 397-410	
3	Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30: Morphologic Documentation from Didactic Cases of [illegible]. *European Urology*, **2020**, 77, e102-e102	10.2
2	Re: Bas W.G. van Rhijn, Anouk E. Hentschel, Johannes Bründl, et al. Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology [illegible]. *European Urology Oncology*, 2021, 4, 183-91	6.7
1	Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate. *European Urology*, **2021**, 80, e81-e82	10.2